Nova Mentis Life Sciences Corp. NMLSF

Overview

Nova Mentis Life Science Corp., operating globally, emerges as a pioneering biotechnology entity dedicated to the forefront of therapeutic and diagnostic advancements. Initially founded in 2004 and formerly known as Liberty Leaf Holdings Ltd., the company underwent a significant rebranding to Nova Mentis Life Science Corp. in June 2020, marking a new chapter in its mission. With its headquarters in Vancouver, Canada, the organization's strategic operations span the development of state-of-the-art diagnostics and psilocybin-based therapeutics, targeting neuroinflammatory conditions with a laser focus on autism spectrum disorder and fragile X syndrome. This ambitious endeavor is bolstered by a collaborative research agreement with the University of Central Florida (UCF), aiming to pioneer a saliva serotonin assay, a testament to the company's commitment to groundbreaking scientific research.

Products and Services

• Psilocybin-based Therapeutics
  

  At the heart of Nova Mentis Life Science Corp.'s product pipeline lies its innovative psilocybin-based therapeutics. This cutting-edge treatment is designed to target neuroinflammatory conditions, with a significant emphasis on autism spectrum disorder and fragile X syndrome. Leveraging the psychedelic compound psilocybin, the company strives to unlock new therapeutic possibilities, aiming to alleviate symptoms and improve the quality of life for individuals affected by these conditions.

• Saliva Serotonin Assay Development
  

  In collaboration with the University of Central Florida (UCF), Nova Mentis is in the process of developing a groundbreaking saliva serotonin assay. This diagnostic tool represents a significant leap forward in the non-invasive measurement of serotonin levels, a crucial neurotransmitter involved in mood regulation, digestion, sleep, and cognition. The assay is tailored for individuals with neuroinflammatory conditions, particularly focusing on autism spectrum disorder and fragile X syndrome, offering a promising avenue for early detection and personalized treatment strategies.